All In Biotech

Drug Trial Radar · NCT07185139

MSCohi-O Lenses for Ocular Involvement in Sjögren's Syndrome

Exploratory Clinical Trial of MSCohi-O Lenses for Ocular Involvement in Sjögren's Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

Aug 30, 2026

Study completion Sep 30, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is aSingle-center, multiple-dosing, prospective, nonrandom, single-arm trial.

Conditions

  • Sjögren's Syndrome

Interventions

  • MSCohi-O LensesDrug

    Each subject will wear MSCohi-O Lenses for 12 hours a day, totally 14 wearings.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: from subjects receiving administration to Day 29 post-administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.